https://www.optimumcomms.com/wp-content/uploads/2025/12/Oncoinvent_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-06-18 08:33:462026-06-18 08:33:46Oncoinvent achieves 50% recruitment milestone in Phase 2 ovarian cancer study of Radspherin®
https://www.optimumcomms.com/wp-content/uploads/2025/12/Oncoinvent_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-06-18 08:33:462026-06-18 08:33:46Oncoinvent achieves 50% recruitment milestone in Phase 2 ovarian cancer study of Radspherin®
https://www.optimumcomms.com/wp-content/uploads/2023/02/AMSilk_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-06-17 10:16:522026-06-17 10:17:19Christian Wichert appointed Chief Executive Officer to lead next phase of growth
https://www.optimumcomms.com/wp-content/uploads/2024/05/Template_Logo_300x180px-80x80Web_Logos-1.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-06-17 08:31:552026-06-17 08:31:55Resolution Therapeutics extends inflammatory and fibrotic disease pipeline with in vivo Regenerative Macrophage Therapy
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-06-16 08:32:032026-06-16 08:32:03Poolbeg Pharma plc – Decision to grant European Patent received for POLB 001 in cancer immunotherapy-induced CRS
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-06-15 08:07:142026-06-15 08:07:14Hansa Biopharma appoints Adam Cutler as new Chief Financial Officer
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-06-12 11:16:422026-06-12 11:17:05Hansa Biopharma invite to Capital Markets Day 2026 in New York
https://www.optimumcomms.com/wp-content/uploads/2026/04/Scenic-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-06-11 14:19:052026-06-11 14:19:05Scenic Biotech Joins Michael J. Fox Foundation’s LITE Program to Explore New Disease-Modifying Approach for Parkinson’s Disease
https://www.optimumcomms.com/wp-content/uploads/2026/06/oriva-website-logo.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-06-11 08:42:532026-06-11 08:42:53Oriva Therapeutics appoints Dr Agnès Arbat as CEO to advance clinical-stage women’s health pipeline
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-06-11 07:10:482026-06-11 08:42:20Poolbeg Pharma plc – Two posters with POLB 001 preclinical data presented at the European Hematology Association Congress
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-06-11 07:10:272026-06-11 08:37:50Poolbeg Pharma announces successful site activation for POLB 001 TOPICAL clinical trial
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-06-10 08:56:492026-06-10 08:56:49Hansa Biopharma appoints Fredrik Röök as VP Business Development
https://www.optimumcomms.com/wp-content/uploads/2026/01/Connecta_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-06-10 08:36:122026-06-10 08:36:12CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome
https://www.optimumcomms.com/wp-content/uploads/2023/02/Sofinnova_Logo_300-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-06-10 07:02:572026-06-10 07:02:57Sofinnova Partners launches collaboration with AWS to scale AI across life sciences innovation
https://www.optimumcomms.com/wp-content/uploads/2025/09/DaltonTx.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-06-04 08:50:022026-06-04 08:50:02DaltonTx launches its drug discovery platform, Dalton, and announces Sygnature Discovery collaboration
https://www.optimumcomms.com/wp-content/uploads/2025/01/Ona_Therapeutics_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-06-04 08:00:442026-06-04 08:00:44Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development
https://www.optimumcomms.com/wp-content/uploads/2025/09/Hansa-Biopharma.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2026-06-02 13:23:162026-06-02 13:23:16Hansa Biopharma participating in Jefferies Global Healthcare Conference in New YorkWe’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
